• Mónica Sorribas Morlán, Miguel Ángel Galmés Garau, Magdalena Esteva Cantó, Alfonso Leiva Rus, and Miguel Román-Rodríguez.
• Atención Primaria de Mallorca, IBSalut, Palma, Baleares, España.
• Aten Primaria. 2020 Nov 1; 52 (9): 600-607.

ObjectiveTo determine the number of short-acting beta-agonists (SABA) canisters dispensed in a pharmacy during one year that is associated with higher asthma hospitalization risk in the same period in patients with active asthma. Multi-centre cross-sectional descriptive design.LocationPrimary care, MAJORICA cohort including sociodemographic, clinical and electronic prescription system data coded during clinical practice from 68,578 patients with COPD and asthma in the Balearic Islands.ParticipantsA total of 7,648 patients older than 18 years with active asthma, who got any SABA canister from the pharmacy during the 2014-2015 period were included. COPD patients were excluded.Main MeasurementsAsthma hospitalization, respiratory medication, tobacco, co-morbidities, age and gender.ResultsMean age 47 years, 38% women, 23.2% active smokers. Seventy-seven patients (1%) were admitted for asthma exacerbation in the study period. Patients who received more than 8 SABA containers per year increased the risk of hospitalization (OR 2.81; 95% CI 1.27-6.24). Severity by therapeutic step and amount of inhaled corticosteroids, as well as heart failure and sleep apnea were also significantly associated with hospitalization.ConclusionsThere is a significant association between the risk of hospitalization and the higher number of SABA canisters dispensed from the pharmacy. The number of canisters/year that best defines a higher risk of hospitalization is≥8 and could be used to identify asthma at risk.Copyright © 2020 The Authors. Publicado por Elsevier España, S.L.U. All rights reserved.

19 keywords...

hide…